BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 16344253)

  • 1. Variability of prostate brachytherapy pre-implant dosimetry: a multi-institutional analysis.
    Merrick GS; Butler WM; Wallner KE; Blasko JC; Michalski J; Aronowitz J; Grimm P; Moran BJ; McLaughlin PW; Usher J; Lief JH; Allen ZA
    Brachytherapy; 2005; 4(4):241-51. PubMed ID: 16344253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of urinary catheterization on dosimetry after prostate implant brachytherapy with palladium-103 or iodine-125.
    Shirvani SM; Kudchadker RJ; Bruno TL; Likhacheva A; Swanson DA; Frank SJ
    Brachytherapy; 2011; 10(4):269-74. PubMed ID: 21296031
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive I-125 multi-seed comparison for prostate brachytherapy: dosimetry and visibility analysis.
    Al-Qaisieh B; Smith DW; Brearley E; St Clair S; Bownes P
    Radiother Oncol; 2007 Aug; 84(2):140-7. PubMed ID: 17588696
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of the radial function on I-125 seeds used for permanent prostate implantation.
    Pickett B; Pouliot J
    Med Dosim; 2004; 29(3):204-9. PubMed ID: 15324917
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isotope selection for permanent prostate implants? An evaluation of 103Pd versus 125I based on radiobiological effectiveness and dosimetry.
    Dicker AP; Lin CC; Leeper DB; Waterman FM
    Semin Urol Oncol; 2000 May; 18(2):152-9. PubMed ID: 10875458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dosimetry of an extracapsular anulus following permanent prostate brachytherapy.
    Merrick GS; Butler WM; Wallner KE; Allen ZA; Kurko B; Anderson RL; Grammer R; Galbreath RW; True L; Adamovich E
    Am J Clin Oncol; 2007 Jun; 30(3):228-33. PubMed ID: 17551297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A study of a pretreatment method to predict the number of I-125 seeds required for prostate brachytherapy.
    Al-Qaisieh B; Brearley E; St Clair S; Flynn A
    Int J Radiat Oncol Biol Phys; 2006 May; 65(1):304-7. PubMed ID: 16618585
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparative study of seed localization and dose calculation on pre- and post-implantation ultrasound and CT images for low-dose-rate prostate brachytherapy.
    Ali I; Algan O; Thompson S; Sindhwani P; Herman T; Cheng CY; Ahmad S
    Phys Med Biol; 2009 Sep; 54(18):5595-611. PubMed ID: 19717887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is a loose-seed nomogram still valid for prostate brachytherapy in a stranded-seed era?
    Kudchadker RJ; Swanson DA; Kuban DA; Lee AK; Bruno TL; Frank SJ
    Int J Radiat Oncol Biol Phys; 2008 Oct; 72(2):623-7. PubMed ID: 18410998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Inter-institutional variation of implant activity for permanent prostate brachytherapy.
    Aronowitz JN; Crook JM; Michalski JM; Sylvester JE; Merrick GS; Mawson C; Pratt D; Naidoo D; Butler WM; Karolczuk K
    Brachytherapy; 2008; 7(4):297-300. PubMed ID: 18786866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Favorable toxicity and biochemical control using real-time inverse optimization technique for prostate brachytherapy.
    Raben A; Rusthoven KE; Sarkar A; Glick A; Benge B; Jacobs D; Raben D
    Brachytherapy; 2009; 8(3):297-303. PubMed ID: 19213608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factors predicting for urinary incontinence after prostate brachytherapy.
    McElveen TL; Waterman FM; Kim H; Dicker AP
    Int J Radiat Oncol Biol Phys; 2004 Aug; 59(5):1395-404. PubMed ID: 15275725
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of intraoperative dosimetric implant representation with postimplant dosimetry in patients receiving prostate brachytherapy.
    Stone NN; Hong S; Lo YC; Howard V; Stock RG
    Brachytherapy; 2003; 2(1):17-25. PubMed ID: 15062159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An innovative dosimetric model for formulating a semi-analytical solution for the activity-volume relationship in prostate implants.
    Lee PC; Parks EK; Moran BJ
    Med Dosim; 2003; 28(4):243-53. PubMed ID: 14684189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Brachytherapy for prostate cancer: summary of American Brachytherapy Society recommendations.
    Nag S
    Semin Urol Oncol; 2000 May; 18(2):133-6. PubMed ID: 10875454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dosimetry accuracy as a function of seed localization uncertainty in permanent prostate brachytherapy: increased seed number correlates with less variability in prostate dosimetry.
    Su Y; Davis BJ; Furutani KM; Herman MG; Robb RA
    Phys Med Biol; 2007 Jun; 52(11):3105-19. PubMed ID: 17505092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improvement of transperineal implant dosimetry by intraoperative cystoscopic confirmation of prostate anatomy.
    Baird MC; Holt RW; Selby TL
    J Urol; 2000 Aug; 164(2):406-10. PubMed ID: 10893597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A comparison of the precision of seeds deposited as loose seeds versus suture embedded seeds: a randomized trial.
    Kaplan ID; Meskell PM; Lieberfarb M; Saltzman B; Berg S; Holupka EJ
    Brachytherapy; 2004; 3(1):7-9. PubMed ID: 15110307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prostate brachytherapy seed migration and dosimetry: analysis of stranded sources and other potential predictive factors.
    Fuller DB; Koziol JA; Feng AC
    Brachytherapy; 2004; 3(1):10-9. PubMed ID: 15110308
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The nature and extent of urinary morbidity in relation to prostate brachytherapy urethral dosimetry.
    Neill M; Studer G; Le L; McLean M; Yeung I; Pond G; Crook JM
    Brachytherapy; 2007; 6(3):173-9. PubMed ID: 17681239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.